Brian Orelli, PhD

Goldman Sachs likes the biotech's prospects.

The biotech gained FDA approval for its aspirin-containing medication, Yosprala.

A new manufacturing process for the biotech's LentiGlobin gene therapy could result in higher cure rates.

Investors aren't happy about the medical imaging company's decision to sell additional shares.

The biotech's partner plans to submit an application for approval by the end of the year.

What the biotech didn't say might have caused its downfall.

Biotech value investing is possible, but don't get get caught in a value trap.

A patent review board rules that claims on Teva Pharmaceuticals' three-times-weekly version of Copaxone aren't patentable.

The generic-drug maker reports a solid fiscal fourth quarter, but it's likely the future that has investors excited.

The development-stage biotech raises capital, diluting shareholders in the process.

With clinical trial data in hand, management highlights the steps remaining to get nusinersen on the market.

Pricing pressure hampers the drugmaker's older insulin drugs.

The development-stage biotech may not have any earnings, but it's producing plenty of data to keep investors interested.

The biodefense company still doesn't know how much BioThrax the government wants to buy. But it should shortly.

The biotech's drugs are on pace to surpass $1 billion cumulatively, but it has pipeline drugs that could each produce that much on their own.

Competition results in lower revenue for the genetic-test maker.

Investors anxiously await its presentation at the American Society of Hematology meeting in December.

The FDA signed off on the biotech's clinical trial design to get mirvetuximab soravtansine approved, but the trial won't have data until 2019.

The biotech remains in a holding pattern, awaiting decisions from the courts and the FDA before it can launch its generic version of three-times-weekly Copaxone.

Second-quarter earnings report sends shares of the specialty pharma soaring.